{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-042791","form_type":"8-K","ticker":"ALKS","cik":"0001520262","company_name":"Alkermes plc.","filed_at":"2024-04-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.800452+00:00","generated_at":"2026-06-04T00:55:10.154425+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"ALKS 2680 shows statistically significant wakefulness improvement in NT2 and IH phase 1b","bullets":["ALKS 2680 improved mean sleep latency vs placebo at all doses in NT2 (5mg: +12 min, p<0.05; 12mg: +19 min, p<0.001; 25mg: +21 min, p<0.001).","In IH cohort, mean sleep latency improved by 8 min (5mg, p<0.05), 11 min (12mg, p<0.01), and 18 min (25mg, p<0.001).","No serious AEs or discontinuations; mild transient TEAEs including pollakiuria, insomnia, dizziness at highest dose.","Phase 2 study in narcolepsy type 2 planned for second half of 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-042791","json":"https://secwatch.observer/filing/0000950170-24-042791.json","markdown":"https://secwatch.observer/filing/0000950170-24-042791.md","text":"https://secwatch.observer/filing/0000950170-24-042791.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1520262/000095017024042791/0000950170-24-042791-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1520262/000095017024042791/alks-20240409.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T00:55:10.154425+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}